<DOC>
	<DOCNO>NCT00058396</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient relapsed refractory chronic lymphocytic leukemia small lymphocytic lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Treating Patients With Relapsed Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine recommend phase II dose IDEC-152 monoclonal antibody patient relapse recurrent chronic lymphocytic leukemia . - Determine safety profile drug patient . - Determine pharmacokinetics pharmacodynamics drug patient . - Determine efficacy drug patient . OUTLINE : This open-label , multicenter , dose-escalation study . Patients receive IDEC-152 monoclonal antibody IV least 2 hour day 1 , 2 , 8 , 15 , 22 . Cohorts 3-10 patient receive escalate dos IDEC-152 monoclonal antibody maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 , 2 6 , 3 10 patient experience dose-limiting toxicity . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 15-50 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm chronic lymphocytic leukemia OR small lymphocytic lymphoma Stage IIIIV OR Stage III , determine disease progression evidence 1 follow characteristic : Rapid double peripheral lymphocyte count Progressive lymphadenopathy Progressive splenomegaly B symptom Grade 2 3 fatigue CD23+ disease Progressive disease least 1 prior chemotherapy course PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy At least 6 month Hematopoietic Platelet count least 50,000/mm^3 Hepatic Bilirubin great 2.0 mg/dL AST/ALT great 1.5 time upper limit normal ( ULN ) Renal Creatinine great 1.5 time ULN Cardiovascular No New York Heart Association class III IV cardiac disease No myocardial infarction within past 6 month No unstable arrhythmia No evidence ischemia EKG within past 14 day Pulmonary FEV_1 least 60 % predict DLCO least 55 % predict Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study treatment HIV negative No secondary malignancy require active treatment ( except hormonal therapy ) No serious nonmalignant disease would preclude study participation No active uncontrolled bacterial , viral , fungal infection No clinically active autoimmune disease PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior anticancer biologic therapy More 4 week since prior anticancer radioimmunotherapy No prior exposure IDEC152 antiCD23 antibody Chemotherapy See Disease Characteristics More 4 week since prior anticancer chemotherapy Endocrine therapy Concurrent hormonal therapy allow second malignancy Radiotherapy More 4 week since prior anticancer radiotherapy Surgery More 4 week since prior major surgery ( except diagnostic surgery ) Other More 4 week since prior anticancer investigational therapy No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
</DOC>